{"id":"stsp-0601-for-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"STSP-0601 combines human serum albumin with interferon alpha to improve the pharmacokinetic properties and biological activity of interferon. The albumin fusion extends the half-life and reduces immunogenicity while maintaining the interferon alpha-mediated antiviral and immune-stimulating effects through JAK-STAT pathway activation.","oneSentence":"STSP-0601 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:33.552Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B"},{"name":"Chronic hepatitis C"}]},"trialDetails":[{"nctId":"NCT06922045","phase":"PHASE3","title":"Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients","status":"RECRUITING","sponsor":"Jiangsu BioJeTay Biotechnology Co., Ltd.","startDate":"2025-03-26","conditions":"Hemophilia","enrollment":32},{"nctId":"NCT06289166","phase":"PHASE2","title":"Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2024-03-18","conditions":"Hemophilia","enrollment":25},{"nctId":"NCT05027230","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2021-10-12","conditions":"Hemophilia","enrollment":77},{"nctId":"NCT04747964","phase":"PHASE1","title":"A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2020-01-15","conditions":"Hemophilia","enrollment":16},{"nctId":"NCT05619926","phase":"PHASE2","title":"Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor","status":"COMPLETED","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2023-01-09","conditions":"Hemophilia","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"STSP-0601 for Injection","genericName":"STSP-0601 for Injection","companyName":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","companyId":"staidson-beijing-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"STSP-0601 for Injection is being studied in a Phase 2 trial for its safety and efficacy in treating adult patients with hemophilia A or B without inhibitor. The exact mechanism of STSP-0601 is currently unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}